Introduction – Triple-negative breast cancer (TNBC) is a less common but more aggressive molecular subtype of breast cancer that is found particularly in younger patients. Although it has no specific therapeutic target, the discovery of its high immunogenicity has led to the development of new immunotherapy treatments, including in neoadjuvant settings. However, to better understand and predict response to treatment, more detailed immune characterization is needed. Methods – After characterizing 91 TNBCs by flow cytometry (FC), 19 of these tumors were characterized by multiplex IHC using Hyperion technique, and 25 by transcriptomic analysis. In parallel, a mouse model was developed, as was a prospective radiomic study. Results – After characterization of immune subpopulations by FC, only Th2 CD4+ T cells (CD4+ TC) had a prognostic value for recurrence free and overall survival, particularly stronger than TILs. Orthogonal validation attempts found values for CD45+ leukocytes, CD4+TCs, and even CD8+TCs that correlated in IHC and transcriptomics, but lacked the power to do so for Th2 cells. Besides, to improve correlation with current neoadjuvant regimens, a mouse model was created to study immune subpopulations, and a radiomic analysis was performed on a prospective cohort. Conclusion – Th2 CD4+ TCs measured by FC have a prognostic value in adjuvant therapy settings, but this value, like their predictive one, remains to be proven in neoadjuvant settings by various techniques that can be used in clinical practice.